Coherus Oncology (NASDAQ:CHRS – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.
A number of other research analysts have also issued reports on the stock. Weiss Ratings lowered shares of Coherus Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 10th. HC Wainwright began coverage on shares of Coherus Oncology in a research report on Thursday, October 29th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.00.
Get Our Latest Report on Coherus Oncology
Coherus Oncology Stock Performance
Shares of CHRS opened at $0.53 on Friday. The company has a debt-to-equity ratio of 2.08, a quick ratio of 1.45 and a current ratio of 1.51. The stock has a market capitalization of $81.19 million, a P/E ratio of -0.54 and a beta of 1.03. The company’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.47. Coherus Oncology has a 1 year low of $0.50 and a 1 year high of $2.62.
Coherus Oncology (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). Coherus Oncology had a negative return on equity of 274.46% and a negative net margin of 253.43%. The firm had revenue of $14.27 million for the quarter, compared to analysts’ expectations of $15.90 million. On average, sell-side analysts predict that Coherus Oncology will post -0.83 earnings per share for the current year.
Institutional Investors Weigh In On Coherus Oncology
Hedge funds and other institutional investors have recently bought and sold shares of the business. Spark Investment Management LLC purchased a new stake in shares of Coherus Oncology during the 2nd quarter worth $25,000. Cetera Investment Advisers acquired a new position in shares of Coherus Oncology during the 1st quarter worth $54,000. The Manufacturers Life Insurance Company purchased a new position in shares of Coherus Oncology in the 2nd quarter valued at about $54,000. Dimensional Fund Advisors LP purchased a new position in shares of Coherus Oncology in the 1st quarter valued at about $60,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Coherus Oncology in the 2nd quarter valued at about $131,000. Institutional investors and hedge funds own 72.82% of the company’s stock.
Coherus Oncology Company Profile
Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.
Further Reading
- Five stocks we like better than Coherus Oncology
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Coherus Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
